JP2017505605A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505605A5
JP2017505605A5 JP2016545896A JP2016545896A JP2017505605A5 JP 2017505605 A5 JP2017505605 A5 JP 2017505605A5 JP 2016545896 A JP2016545896 A JP 2016545896A JP 2016545896 A JP2016545896 A JP 2016545896A JP 2017505605 A5 JP2017505605 A5 JP 2017505605A5
Authority
JP
Japan
Prior art keywords
mycobacterial
fusion
nucleic acid
hetero
immunogenic combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016545896A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505605A (ja
JP6605480B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/050344 external-priority patent/WO2015104380A1/en
Publication of JP2017505605A publication Critical patent/JP2017505605A/ja
Publication of JP2017505605A5 publication Critical patent/JP2017505605A5/ja
Application granted granted Critical
Publication of JP6605480B2 publication Critical patent/JP6605480B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016545896A 2014-01-09 2015-01-09 ヘテロオリゴマーマイコバクテリア抗原の融合物 Expired - Fee Related JP6605480B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14305030 2014-01-09
EP14305030.0 2014-01-09
PCT/EP2015/050344 WO2015104380A1 (en) 2014-01-09 2015-01-09 Fusion of heterooligomeric mycobacterial antigens

Publications (3)

Publication Number Publication Date
JP2017505605A JP2017505605A (ja) 2017-02-23
JP2017505605A5 true JP2017505605A5 (enExample) 2018-02-22
JP6605480B2 JP6605480B2 (ja) 2019-11-13

Family

ID=49989636

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016545896A Expired - Fee Related JP6605480B2 (ja) 2014-01-09 2015-01-09 ヘテロオリゴマーマイコバクテリア抗原の融合物

Country Status (12)

Country Link
US (1) US10765731B2 (enExample)
EP (1) EP3092000A1 (enExample)
JP (1) JP6605480B2 (enExample)
KR (1) KR20160130216A (enExample)
CN (1) CN106103471B (enExample)
BR (1) BR112016015936A2 (enExample)
CA (1) CA2936131A1 (enExample)
IL (1) IL246659A0 (enExample)
MX (1) MX2016009072A (enExample)
RU (1) RU2695462C2 (enExample)
SG (1) SG11201605595YA (enExample)
WO (1) WO2015104380A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357555B2 (en) * 2012-07-10 2019-07-23 Transgene Sa Mycobacterial antigen vaccine
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CN105601747B (zh) * 2015-10-21 2019-05-28 中山大学 一种结核杆菌融合蛋白及其在诱导外周血单个核细胞产生细胞因子的应用
CN105218680B (zh) * 2015-10-21 2019-06-25 中山大学 一种用于诱导外周血单个核细胞产生细胞因子的结核分支杆菌融合蛋白
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
US20200148729A1 (en) * 2016-05-21 2020-05-14 Infectious Disease Research Institute Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections
EP3474889A4 (en) 2016-06-22 2020-04-29 International AIDS Vaccine Initiative, Inc. RECOMBINANT CYTOMEGALOVIRUS VECTORS FOR USE AS TUBERCULOSIS VACCINES
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2019079155A1 (en) 2017-10-17 2019-04-25 International Aids Vaccine Initiative, Inc. CASSETTES OF ANTIGENS OF TUBERCULOSIS
KR102004902B1 (ko) * 2017-12-26 2019-07-29 연세대학교 산학협력단 융합 단백질을 포함하는 결핵 예방용 조성물
CN110684116B (zh) * 2019-08-23 2022-04-26 成都可恩生物科技有限公司 一种结核分枝杆菌eec融合蛋白、制备方法及其应用
CN110590957B (zh) * 2019-09-11 2021-06-01 中国人民解放军总医院第八医学中心 一种融合蛋白及其在抗结核分枝杆菌的免疫保护中的应用
RU2724896C1 (ru) * 2019-11-14 2020-06-26 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Полиантигенная вакцина для профилактики и вспомогательного лечения туберкулеза
CN111269297B (zh) * 2020-01-23 2021-11-30 郑州伊美诺生物技术有限公司 一种结核分枝杆菌刺激抗原的制备方法
EP4565266A1 (en) * 2022-08-03 2025-06-11 Nanoramic, Inc. Rna for preventing or treating tuberculosis
WO2024027910A1 (en) * 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
CN116162141B (zh) * 2022-11-30 2024-04-12 中国疾病预防控制中心传染病预防控制所 一种结核分枝杆菌抗原epcra013及其应用
CN116063418B (zh) * 2022-12-08 2024-04-12 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌抗原组合物epdpa015及其制备方法与应用
CN116106544A (zh) * 2023-01-10 2023-05-12 南京农业大学 一种牛分枝杆菌抗体检测试剂盒

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
AU672359B2 (en) 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
PL341697A1 (en) * 1997-12-23 2001-04-23 Genesis Res & Dev Corp Ltd Compositions derived from mycobacterium vaccae and methods of using them
US6328978B1 (en) * 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
ATE332364T1 (de) 1999-02-22 2006-07-15 Transgene Sa Verfahren zur gewinnung von purifizierter virenzuammensetzung
EP1816204B1 (en) 1999-05-17 2010-10-20 Crucell Holland B.V. Recombinant Adenovirus of the Ad26 serotype
DE20122302U1 (de) 2000-11-23 2005-02-24 Bavarian Nordic A/S Variante des Modifizierten Vaccinia-Ankara-Virus
US7393539B2 (en) 2001-06-22 2008-07-01 Health Protection Agency Mycobacterial antigens expressed under low oxygen tension
EP2196473A1 (en) 2001-07-04 2010-06-16 Health Protection Agency Mycobacterial antigens expressed during latency
UA82466C2 (uk) 2001-07-18 2008-04-25 Бавариан Нордика А/С Спосіб посилення ампліфікації хордопоксвірусу
GB0125535D0 (en) 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency
WO2003053463A2 (en) 2001-12-10 2003-07-03 Bavarian Nordic A/S Poxvirus-containing compositions and process for their preparation
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
EP1523331B1 (en) 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
WO2004083418A1 (en) 2003-03-17 2004-09-30 Merck & Co., Inc. Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
US20040191222A1 (en) 2003-03-28 2004-09-30 Emini Emilio A. Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby
WO2005061534A2 (en) * 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
ES2871907T3 (es) 2004-01-23 2021-11-02 Msd Italia Srl Portadores de vacuna de adenovirus de chimpancé
EP2497831B1 (en) * 2004-05-25 2014-07-16 Oregon Health and Science University TB vaccination using HCMV-based vaccine vectors
US20060024332A1 (en) * 2004-08-02 2006-02-02 Waters Wade R Recombinant ESAT-6:CFP-10 fusion protein useful for specific diagnosis of tuberculosis
WO2006026404A2 (en) * 2004-08-26 2006-03-09 Sequella, Inc. Assay for detecting tuberculosis in nonhuman primates
MX2007008182A (es) * 2005-01-05 2008-02-19 Isis Innovation Composiciones para inmunizar contra micobacteria.
WO2006104389A1 (en) 2005-03-31 2006-10-05 Leiden University Medical Center Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease
AU2006261445B2 (en) * 2005-06-23 2011-03-31 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
NZ597557A (en) * 2006-03-02 2013-10-25 Uab Research Foundation Mycobacterial disease detection, treatment, and drug discovery
KR101141333B1 (ko) 2006-06-20 2012-05-23 트랜스진 에스.에이. 재조합 바이러스 백신
MX2009010800A (es) * 2007-04-04 2010-01-29 Infectious Disease Res Inst Id Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
WO2009003474A1 (en) 2007-06-29 2009-01-08 Statens Serum Institut The use of monomycolyl glycerol (mmg) as an adjuvant
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
CN101688182A (zh) 2007-07-03 2010-03-31 特兰斯吉恩股份有限公司 永生化禽细胞系
CN101376891B (zh) * 2007-08-27 2012-05-23 上海生物制品研究所有限责任公司 新型结核病疫苗的制备及其应用
US7935354B2 (en) 2007-11-13 2011-05-03 Aeras Global Tb Vaccine Foundation Generation of new BCG vaccine strains protecting against the establishment of latent Mycobacterium tuberculosis infection and reactivation from the latent or persistent state
WO2010034007A2 (en) 2008-09-22 2010-03-25 Oregon Health & Science University Methods for detecting a mycobacterium tuberculosis infection
EP2344542A2 (en) * 2008-09-24 2011-07-20 Adjuvantix Limited Tubercolosis vaccines targeted to cd40
CN101538578B (zh) * 2009-03-02 2011-01-26 华中农业大学 三基因融合的重组牛结核特异性抗原蛋白及制备方法
CN102413837B (zh) * 2009-04-24 2015-11-25 国立血清研究所 预防再激活的结核病tb疫苗
KR20120026526A (ko) 2009-05-12 2012-03-19 트랜스진 에스.에이. 불멸화 조류 세포주 및 그의 용도
US9610343B2 (en) 2009-05-20 2017-04-04 Aeras Global Tb Vaccine Foundation Stable, spray dryed, immunogenic, viral compositions
GB201007790D0 (en) * 2010-05-10 2010-06-23 Isis Innovation Compositions
GB201008512D0 (en) * 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
CN101900727A (zh) * 2010-06-01 2010-12-01 华中农业大学 一种应用Rv3872新型融合蛋白制备的牛结核抗体鉴别检测试纸条
WO2012031752A2 (en) 2010-09-07 2012-03-15 Institut Pasteur Korea Tuberculosis mutants
WO2012057904A1 (en) * 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
EP2688591A4 (en) * 2011-03-22 2014-10-01 Baylor Res Inst TARGETING DENDRITIC CELLS FOR A TUBERCULOSIS VACCINE
CN102692509B (zh) * 2012-05-11 2014-11-26 中国农业科学院北京畜牧兽医研究所 重组蛋白混合物介导的牛结核病诊断方法及其试剂
WO2014009433A1 (en) * 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
US10357555B2 (en) * 2012-07-10 2019-07-23 Transgene Sa Mycobacterial antigen vaccine
CN102719438B (zh) * 2012-07-12 2013-10-30 章晓联 一种能特异结合结核菌抗原的核酸适配子及其应用
CN104736555B (zh) * 2012-10-23 2019-06-21 国家血清研究所 结核分枝杆菌疫苗
CN103333251B (zh) * 2013-04-11 2014-08-20 广西壮族自治区动物疫病预防控制中心 基于重组融合抗原蛋白的γ-干扰素夹心ELISA检测方法
CN103204945A (zh) * 2013-05-03 2013-07-17 扬州大学 一种用于牛结核病诊断的真核表达cfp10-esat-6融合蛋白
EP3013364B1 (en) 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
CN103386128B (zh) * 2013-07-02 2017-02-08 中国食品药品检定研究院 一种含联合佐剂的结核亚单位疫苗

Similar Documents

Publication Publication Date Title
JP2017505605A5 (enExample)
JP2015524794A5 (enExample)
RU2016131853A (ru) Гибридизация гетероолигомерных микобактериальных антигенов
US11224646B2 (en) Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis
TWI638829B (zh) 分枝桿菌抗原疫苗
JP6470179B2 (ja) 結核菌(m.tuberculosis)ワクチン
JP2015533841A5 (enExample)
JP2012524733A5 (enExample)
JP2016510989A5 (enExample)
US11021534B2 (en) Mycobacterial antigen composition
Abu et al. Tuberculosis: looking beyond BCG vaccines
CN106237317A (zh) 由结核分枝杆菌抗原组成的结核疫苗
CN101451145A (zh) 基于t细胞表位的结核基因疫苗及其制备方法和应用
CN116003540A (zh) 一种结核分枝杆菌抗原组合物pfhp010的制备及其应用
Peeridogaheh et al. Evaluation of immune responses to a DNA vaccine encoding Ag85a-Cfp10 antigen of Mycobacterium tuberculosis in an animal model
CN104127883B (zh) 以hsp65为表位支架的多t细胞表位结核基因疫苗
JP6451933B2 (ja) ワクチン及びプライムブーストワクチン
Tsujimura et al. Allergy vaccines using a mycobacterium-secreted antigen, Ag85B, and an IL-4 antagonist
Shahzad et al. Cloning, expression and genetic immunization studies of Mycobacterium tuberculosis gene esat6
Gu et al. Improved immunogenicity of mycobacterium tuberculosis Rv0577 by a heterologous prime-boost vaccination strategy in mice
Yamamura et al. Immunogenicity of latency-associated antigens of Mycobacterium tuberculosis in DNA-vaccinated mice
Jain et al. Development of Candidate Vaccines for Protection Against Tuberculosis
WO2025129174A1 (en) Compositions and methods for treating mycobacterial infection
CA2598078A1 (en) Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis
Tiwari et al. International Journal of Drug Development & Research| April-June 2011| Vol. 3| Issue 2| ISSN 0975-9344| Available online http://www. ijddr. in Covered in Official Product of Elsevier, The Netherlands© 2010 IJDDR